Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Inclusion Criteria: * Pathologically or cytologically confirmed diagnosis of unresectable Stage III non-small cell lung cancer as judged by the investigator. * Tissue or blood samples tested and confirmed to be positive for EGFR sensitive mutation * ECOG Performance Status of 0-1 * At least one measurable lesion according to RECIST 1.1 * Adequate organ and marrow function Exclusion Criteria: * Histologically or cytologically confirmed combined SCLC and NSCLC, large cell neuroendocrine carcinoma, and sarcoma-like carcinoma * The presence of malignant pleural effusion * Prior systemic anti-cancer therapy for non-small cell lung cancer * Prior local radiotherapy for NSCLC * Patients with uncontrolled gastrointestinal diseases that may affect the absorption of test drugs (such as Crohn's disease, ulcerative colitis, absorption disorders, or diarrhea of any cause ≥ Grade 2 CTCAE) according to the investigator's assessment